Most Read Articles
01 Sep 2016
Digoxin, as a new or preexisting therapy, does not increase mortality following acute phase of ST-elevation myocardial infarction (STEMI), as shown in the MAGIC study.
15 Apr 2016
Addition of digoxin to an ACE inhibitor lessens heart failure (HF) hospitalisation in HF patients with reduced ejection fraction, regardless of diabetes status, as presented in an analysis of the Digitalis Investigation Group trial.
22 Mar 2017
Patients often seek consultation at the pharmacy for superficial skin infection. The goal of this activity is to improve pharmacists' knowledge on strategies to manage bacterial skin infection.
 
Please click here to access this module
01 Sep 2017
Complementary medicines can play an important part in maintaining wellness, preventing deficiencies and optimizing health outcomes, says Dr Lesley Braun PhD, Director of the Blackmores Institute. 

Two-year tocilizumab regimen shows potential in early RA

Audrey Abella
6 days ago

The interleukin-6 receptor-alpha inhibitor tocilizumab alone or in combination with methotrexate demonstrated clinical benefit after 2 years of treatment in methotrexate-naïve patients with early rheumatoid arthritis (RA), according to the FUNCTION* trial.

A total of 1,157 methotrexate-naive patients with early (≤2 years) active and progressive RA were randomized 1:1 to receive intravenous tocilizumab at doses of 4 mg/kg or 8 mg/kg every 4 weeks in combination with oral methotrexate or as monotherapy (8 mg/kg only), or methotrexate monotherapy (initial dose of 7.5 mg/week to a maximum of 20 mg/week at week 8 if joints were tender or swollen) for 104 weeks, about 70 percent of whom (n=809) completed treatment.

At week 52, 33 percent of patients in the 4 mg/kg tocilizumab + methotrexate group and 49 percent of patients on methotrexate monotherapy switched to escape therapy using 8 mg/kg tocilizumab + methotrexate. [Ann Rheum Dis 2017;76:1279-1284]

DAS28-ESR** remission rates were achieved by nearly half of the participants in the 8 mg/kg tocilizumab + methotrexate group (49.3 percent and 47.6 percent at weeks 52 and 104, respectively) vs those in the 4 mg/kg tocilizumab + methotrexate (36.1 percent and 28.1 percent, respectively) and methotrexate monotherapy groups (20.2 percent and 16.0 percent, respectively).

These results suggest that patients in the 8 mg/kg tocilizumab + methotrexate arm exhibited the best response, said the researchers. “Year 2 results show that the efficacy of [tocilizumab] was maintained for extended treatment periods.”

After 52 weeks of escape therapy, DAS28-ESR remission was achieved by 30.5 percent and 51.4 percent of escape subjects (4 mg/kg tocilizumab + methotrexate and methotrexate monotherapy, respectively), which underlines the significance of longer treatment periods to establish efficacy in some patient groups, said the researchers.

Despite improved remission rates, participants in the escape group had lower ACR*** response rates and a greater degree of joint damage, said the researchers, noting the importance of early treatment.

The comparable improvements between the original 8 mg/kg tocilizumab + methotrexate and methotrexate escape arms suggest that serum tocilizumab concentrations between the tocilizumab monotherapy and 8 mg/kg tocilizumab + methotrexate arms were maintained at similar levels, which could indicate the lack of additive effect of methotrexate on serum drug levels. [Ann Rheum Dis 2015;74:1037-1044]

Overall, tocilizumab monotherapy or the 8 mg/kg tocilizumab + methotrexate combination resulted in sustained improvement and inhibited joint damage at year 2, said the researchers. “Maintenance of response with 8 mg/kg [tocilizumab] monotherapy suggests that early [tocilizumab] therapy is a viable option for patients intolerant of methotrexate.”

Given the large number of patients who shifted to escape therapy, the researchers recommended exercising caution when interpreting the findings of this group.

 

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Pharmacy - Malaysia digital copy today!
DOWNLOAD
Editor's Recommendations
Most Read Articles
01 Sep 2016
Digoxin, as a new or preexisting therapy, does not increase mortality following acute phase of ST-elevation myocardial infarction (STEMI), as shown in the MAGIC study.
15 Apr 2016
Addition of digoxin to an ACE inhibitor lessens heart failure (HF) hospitalisation in HF patients with reduced ejection fraction, regardless of diabetes status, as presented in an analysis of the Digitalis Investigation Group trial.
22 Mar 2017
Patients often seek consultation at the pharmacy for superficial skin infection. The goal of this activity is to improve pharmacists' knowledge on strategies to manage bacterial skin infection.
 
Please click here to access this module
01 Sep 2017
Complementary medicines can play an important part in maintaining wellness, preventing deficiencies and optimizing health outcomes, says Dr Lesley Braun PhD, Director of the Blackmores Institute.